GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

“Taking these medications puts individuals at risk of everything from allergic reactions to uncontrolled blood sugar levels, ...

The Kokomo woman was prediabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually prescribed ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...

Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...

Losing weight can feel like climbing a mountain with no clear path. The one-size-fits-all advice—like “eat less, move ...

Retatrutide, an experimental drug by Eli Lilly, shows promising results in weight loss by targeting three hormones, ...

Its active ingredient is tirzepatide, which is both a glucose ... loss programs requires 3-month commitment limited professional availability in some areas professional visits not covered by ...

NICE's expert committee notes that wider availability of algorithm-based ... a new treatment for acanthamoeba keratitis. Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular ...

While tirzepatide was on the shortage list ... Citing “legislative history and statutory text,” Lilly said that “commercial availability is not the same as a drug shortage,” but the FDA may see things ...